News
Genetic Analysis announces terms of the previously announced subsequent offering to shareholders of up to appr. NOK 9 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW…
Mandatory notification of trade
OSLO, NORWAY – 20 November 2023: Genetic Analysis AS (“GA” or “the Company”) announces that members of the Board and…
Minutes from the Extraordinary General Meeting
Oslo, Norway, November 20, 2023 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held an Extraordinary General Meeting today, November…
Presentation of GA-map® by Genetic Analysis sparks great interest at xMAP® Connect EMEA in Amsterdam
Genetic Analysis recently participated in xMAP® Connect EMEA, an industry conference November 8-9 in Amsterdam organized by Luminex Corporation –…
Genetic Analysis AS participates at Medica 13-16. November 2023
Commercial director, Mr. Detlef Janke, is attending the Medica Trade Fair in Düsseldorf, Germany. He would be more than happy…
Notice of Extraordinary General Meeting 2023
Notice is hereby served that an extraordinary general meeting in Genetic Analysis AS (the “Company”) will be held on Monday…
Information avseende nyttjandeperiod av teckningsoptioner av serie TO 2 i Genetic Analysis AS
OSLO, NORGE – 3 november, 2023 – Den 8 november 2023 inleds nyttjandeperioden för de teckningsoptioner av serie TO 2…
Correction: Updated intended record date for the intended Subsequent Offering announced in press release, November 2, 2023
Correction of press release regarding subsequent offer
Subscriptions received in separate tranche of previously announced directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW…
Board member resigns at his request
OSLO, NORWAY – November 2, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the…
Genetic Analysis: Launch of GA-map® Discovery – A microbiome profiling offering for Research Customers
GA-map new product Discovery launch
New Luminex whitepaper describes how the GA-map® Dysbiosis Test utilizes xMAP® technology for microbiome profiling
Bacteria residing in the gastrointestinal tract modulate many bodily functions from nutrient metabolism to immune system regulation. This whitepaper describes…